Xilio Therapeutics (XLO) Notes Payables (2020 - 2023)

Xilio Therapeutics has disclosed Notes Payables across 3 years of filings, most recently posting $3.3 million for Q4 2023.

• In Q4 2023, Notes Payables fell 50.28% year-over-year to $3.3 million; the TTM figure through Dec 2023 stood at $3.3 million (down 50.28% YoY), while the FY2023 annual figure was $3.3 million, down 50.28% from the prior year.
• Notes Payables came in at $3.3 million for Q4 2023 at Xilio Therapeutics, down from $5.0 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $7.1 million in Q2 2023 to a low of $1.7 million in Q1 2022.
• Average Notes Payables over 3 years is $4.6 million, with a median of $5.0 million recorded in 2023.
• The largest YoY upside for Notes Payables was 299.94% in 2023 against a maximum downside of 50.28% in 2023.
• Over 3 years, Notes Payables stood at $2.3 million in 2020, then jumped by 185.77% to $6.7 million in 2022, then tumbled by 50.28% to $3.3 million in 2023.
• Per Business Quant data, the three most recent Notes Payables figures were $3.3 million in Q4 2023, $5.0 million in Q3 2023, and $7.1 million in Q2 2023.